VivoSim Labs (VIVS) Competitors $2.56 -0.05 (-1.92%) As of 10/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock VIVS vs. LNAI, CVKD, ENLV, DARE, PASG, SONN, AKTX, MTVA, LPTX, and ALVRShould you be buying VivoSim Labs stock or one of its competitors? The main competitors of VivoSim Labs include Lunai Bioworks (LNAI), Cadrenal Therapeutics (CVKD), Enlivex Therapeutics (ENLV), Dare Bioscience (DARE), Passage Bio (PASG), Sonnet BioTherapeutics (SONN), Akari Therapeutics (AKTX), MetaVia (MTVA), Leap Therapeutics (LPTX), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry. VivoSim Labs vs. Its Competitors Lunai Bioworks Cadrenal Therapeutics Enlivex Therapeutics Dare Bioscience Passage Bio Sonnet BioTherapeutics Akari Therapeutics MetaVia Leap Therapeutics AlloVir VivoSim Labs (NASDAQ:VIVS) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability. Which has preferable valuation and earnings, VIVS or LNAI? VivoSim Labs has higher revenue and earnings than Lunai Bioworks. VivoSim Labs is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVivoSim Labs$142K46.87-$2.48M-$10.20-0.25Lunai BioworksN/AN/A-$178.01M-$7.70-0.16 Do analysts rate VIVS or LNAI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media refer more to VIVS or LNAI? In the previous week, VivoSim Labs had 1 more articles in the media than Lunai Bioworks. MarketBeat recorded 1 mentions for VivoSim Labs and 0 mentions for Lunai Bioworks. VivoSim Labs' average media sentiment score of 1.00 beat Lunai Bioworks' score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media. Company Overall Sentiment VivoSim Labs Positive Lunai Bioworks Neutral Which has more volatility and risk, VIVS or LNAI? VivoSim Labs has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Do institutionals and insiders have more ownership in VIVS or LNAI? 8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 3.7% of VivoSim Labs shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is VIVS or LNAI more profitable? Lunai Bioworks has a net margin of 0.00% compared to VivoSim Labs' net margin of -1,396.48%. VivoSim Labs' return on equity of -32.95% beat Lunai Bioworks' return on equity.Company Net Margins Return on Equity Return on Assets VivoSim Labs-1,396.48% -32.95% -21.31% Lunai Bioworks N/A -222.12%-152.88% SummaryVivoSim Labs beats Lunai Bioworks on 8 of the 12 factors compared between the two stocks. Get VivoSim Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVS vs. The Competition Export to ExcelMetricVivoSim LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.66M$3.43B$6.20B$10.53BDividend YieldN/A2.28%5.70%4.83%P/E Ratio-0.2523.1685.7027.13Price / Sales46.87462.96584.94179.19Price / CashN/A46.9237.1060.81Price / Book0.4610.4112.236.52Net Income-$2.48M-$52.77M$3.33B$276.93M7 Day Performance-15.79%2.31%1.17%1.93%1 Month Performance-38.31%12.59%6.85%2.19%1 Year PerformanceN/A11.18%58.93%34.62% VivoSim Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVSVivoSim Labs1.2206 of 5 stars$2.56-1.9%N/AN/A$6.66M$142K-0.2520Positive NewsShort Interest ↓LNAILunai BioworksN/A$1.24+1.6%N/AN/A$28.74MN/A-0.1620News CoverageCVKDCadrenal Therapeutics2.9148 of 5 stars$14.00-0.7%$32.00+128.6%-21.0%$28.66MN/A-1.584Gap UpENLVEnlivex Therapeutics2.691 of 5 stars$1.16+4.5%$10.00+762.1%-30.3%$28.18MN/A-2.0070News CoverageDAREDare Bioscience2.5327 of 5 stars$2.05-0.5%$10.00+387.8%-45.6%$27.63M$10K-0.9630Positive NewsPASGPassage Bio3.0965 of 5 stars$8.52+0.1%$75.67+788.1%-30.4%$27.09MN/A-0.47130Gap UpSONNSonnet BioTherapeutics1.7032 of 5 stars$3.95-8.4%$20.00+406.3%-41.9%$26.98M$20K0.0010News CoverageAKTXAkari Therapeutics2.644 of 5 stars$0.82-16.3%$3.30+302.5%-66.2%$26.75MN/A0.009News CoverageShort Interest ↑Gap UpHigh Trading VolumeMTVAMetaVia1.6351 of 5 stars$1.09+6.9%$7.50+588.1%N/A$26.38MN/A0.008LPTXLeap Therapeutics2.8537 of 5 stars$0.62+0.5%$3.38+440.9%-79.4%$25.86MN/A-0.3940News CoveragePositive NewsAnalyst DowngradeShort Interest ↓Gap UpALVRAlloVirN/A$5.10+7.1%N/A-74.0%$25.72MN/A-0.25110News CoverageHigh Trading Volume Related Companies and Tools Related Companies Lunai Bioworks Alternatives Cadrenal Therapeutics Alternatives Enlivex Therapeutics Alternatives Dare Bioscience Alternatives Passage Bio Alternatives Sonnet BioTherapeutics Alternatives Akari Therapeutics Alternatives MetaVia Alternatives Leap Therapeutics Alternatives AlloVir Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVS) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VivoSim Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VivoSim Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIVS Stock Alerts